Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1264 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-01

Study Completion Date

2021-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

The disease malaria affects many people in Liberia and other parts of Africa. It is caused by germs that are spread by mosquito bites. It may be mild but can be serious or can lead to death if not diagnosed and treated. Children younger than 5 years old and pregnant women are most at risk of malaria. Worms also infect many people in Liberia. They can be caused by mosquito bites or by touching soil or still water. Worm infections can be mild or serious. Doctors in Liberia and their NIH partners want to learn more about these diseases in women and children.

Objective:

To measure how much malaria and worm infections there are in pregnant women and children in two counties of Liberia.

Eligibility:

Pregnant women ages 18 and older and children ages 6 12 months seeking routine care at C.H. Rennie Hospital or the Duport Road Health Center

Design:

Participants will be screened with questions about their health or their child s health.

Participants will be asked further questions about their health and about their home life.

Participants will give a small amount of blood by finger prick. This will be tested to see if they have malaria or some types of worms, and for research studies.

Participants who are sick from malaria will be treated at a study clinic. Treatment will follow standards of the Liberia and/or the World Health Organization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia

NCT01905436

Lymphatic Filariasis Onchocerciasis Soil Transmitted Helminth (STH) Infections

COMPLETED

Spontaneous Antigenemia in Loiasis

NCT04258670

Loiasis Lymphatic Filariasis

UNKNOWN

Rift Valley Fever in Kenya

NCT00287014

Rift Valley Fever

COMPLETED

Community Acquired Bacteremic Syndromes in Young Nigerian Children

NCT02946775

Community-Acquired Infections

COMPLETED

Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis

NCT05466630

Human African Trypanosomiasis Sleeping Sickness Trypanosoma Brucei Gambiense; Infection +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences, in particular for at-risk populations such as pregnant women and young infants. Pregnancy malaria is associated with low birth weight (LBW), maternal anemia, and gestational hypertension; both inflammation and the fetal response to infection may contribute to these poor outcomes. Placental malaria (PM) is caused by P. falciparum-infected erythrocytes that bind to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta, where they cause disease and may lead to death of the mother and her offspring. Women become resistant to PM as they acquire antibodies that target surface proteins of placental parasites. In areas of stable transmission, acute severe malaria syndromes are limited to children under 5 years of age. The pathogenesis of severe malaria remains poorly understood, although some evidence suggests that parasites causing severe malaria may express distinct antigens on the surface of infected erythrocytes. Thus, vaccines to prevent malarial disease may need to target distinct antigens in order to protect pregnant women or young children.

The primary hypothesis in this study is that the burden of P. falciparum infection around Margibi and Montserrado is sufficient to support future studies of malaria pathogenesis and immunity. In addition to assessing malaria burden this study will build up diagnostic laboratory capacity for malaria diagnostics. We plan to enroll 2920 pregnant women and 2920 children (6-12 months of age) into a cross sectional study that will be conducted in Margibi and Montserrado counties, Liberia. Women presenting for routine antenatal visits and presenting for well-baby clinic visits (e.g. vaccinations, vitamins) at C.H. Rennie Hospital in Margibi or Duport Road Health Center in Montserrado will be enrolled. Samples collected from the women and children will be examined for evidence of infection by Plasmodium and other parasitic diseases in order to assess prevalence in this key reservoir population. For our primary outcome, we will determine the prevalence of P. falciparum infection in these two key demographic groups, including their annual and seasonal variations, as these data will form the basis to design future natural history or interventional studies at these sites. For our secondary outcomes, we will determine the prevalence of other parasitic diseases, such as filaria, S. stercoralis, and schistosomes by serologic assays of blood samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children

Children 6 -12 months of age presenting for routine clinic visits

No interventions assigned to this group

Pregnant Women

Pregnant Women 18 years and older presenting for routine clinic visits

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For pregnant women, a study participant must satisfy the following criteria to be enrolled in this study:

* Pregnant woman \>=18 years of age reporting for routine care at the center without acute illness or abnormal vital signs (e.g.fever, SBP \> 160, OR DBP \> 110) per standard clinic procedures
* The study participant understands the study and gives informed consent for participation
* Willingness to share a positive test result for malaria or helminths with the C.H. Rennie Hospital or the Duport Road Health Center so treatment can be initiated if necessary
* For children, a study participant must satisfy the following criteria to be enrolled in this study:

* Children 6-12 months of age at time of visit presenting for routine care at the center without acute illness or abnormal vital signs (e.g. fever) per standard clinic procedures
* The parent or guardian understands the study and gives informed consent for participation of their child
* Willingness of parent/guardian to share a positive test result for malaria or helminths with the C.H. Rennie Hospital or the Duport Road Health Center so treatment can be initiated if necessary

Exclusion Criteria

* For women, prior enrollment in the study during the same pregnancy
* For children, prior enrollment in the study
* Conditions that in the judgment of the Principal Investigator or Clinical Investigators could adversely impact the safety of the study participant, including conditions that may impair the ability of the participant or participant s parent/guardian to understand the study (examples to consider may include severe acute illness at the time of enrollment, psychiatric conditio (s) that may preclude compliance with the protocol, and suspected or known drug abuse). All such exclusions and the reason for exclusion will be documented.

Minimum Eligible Age

6 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No